Who makes Optimark®?

Optimark® is developed by Daniel S. Berman.

Last reviewed 2026-04-19 · How we verify

Optimark®

Daniel S. Berman · Phase 1 active Small molecule

At a glance

Generic name	Optimark®
Also known as	gadoversetamide, gadolinium, MRI contrast agent, gadolinium contrast
Sponsor	Daniel S. Berman
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Optimark® CI brief — competitive landscape report
Optimark® updates RSS · CI watch RSS
Daniel S. Berman portfolio CI